David Allison, Ph.D. joined Westlake in 2023. Prior to Westlake Dr. Allison was a Partner at 5AM Ventures since 2016 where he was involved in the firm’s investments in CinCor Pharma (acquired by AstraZeneca), Crinetics (NASDAQ: CRNX), Impel Neuropharma (NASDAQ: IMPL), Inipharm, Magnetic Insight, Neurogastrx, Portal Instruments, and Radionetics.
Prior to 5AM, Dr. Allison was a Principal at Versant Ventures where he was involved in the firm’s investments in BlueRock Therapeutics (acquired by Bayer), Crinetics (NASDAQ: CRNX), Aprea (NASDAQ: APRE) and BioTie (acquired by Acorda). Prior to Versant, Dr. Allison worked with the healthcare team at Split Rock Partners and PTV Healthcare Capital.
Dr. Allison received a Ph.D. in Bioengineering from Rice University with a focus on the extracellular matrix in cardiovascular disease. He received a B.S.E in Biomedical Engineering from The University of Iowa.
